1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,839 | 0,869 | 23.07. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.07. | Cereno Scientific - Phase II calling for CS014 after Phase I success | 215 | Edison Investment Research | Cereno Scientific reported positive Phase I readouts for CS014, its novel HDAC inhibitor, paving the way for Phase II studies in idiopathic pulmonary fibrosis (IPF). The candidate demonstrated favourable... ► Artikel lesen | |
| 15.07. | Cereno Scientific AB: Cereno Scientific announces positive topline results from Phase I trial of CS014 - a novel HDAC inhibitor - supporting advancement into Phase II | 59 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced positive... ► Artikel lesen | |
| 30.06. | Cereno Scientific shares that the top-line results of the CS014 Phase I trial will be communicated in mid-July | 4 | Cision News | ||
| 23.06. | Cereno Scientific - Improved liquidity with latest debt financing | 263 | Edison Investment Research | Cereno Scientific has bolstered its liquidity position through a SEK25m loan facility secured from new Danish investors Venusat and SAJ Finans. Concurrently, the company executed an addendum to its... ► Artikel lesen | |
| 20.06. | Cereno Scientific secures 100 MSEK through additional loan financing and conversion to advance HDAC inhibitors CS1 and CS014 in Phase II | 1 | Cision News | ||
| 17.06. | Cereno Scientific - Four-month EAP data support CS1 plans | 273 | Edison Investment Research | Cereno Scientific has announced encouraging four-month follow-up data from its Expanded Access Program (EAP) for CS1, a first-in-class HDAC inhibitor being developed to treat pulmonary arterial hypertension... ► Artikel lesen | |
| 16.06. | Cereno Scientific AB: Cereno Scientific shares 4-month follow-up data from Expanded Access Program in line with Phase IIa trial results of CS1 in rare disease PAH | 145 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced 4-month... ► Artikel lesen | |
| 10.06. | Cereno Scientific AB: Cereno Scientific shares the report from Annual General Meeting 2025 | 164 | GlobeNewswire (Europe) | Today, June 10, 2025 Cereno Scientific AB (publ) held Annual General Meeting at the MAQS Advokatbyrå's premises at Masthamnsgatan 13 in Gothenburg, Sweden. Chairman of the Annual General Meeting (the... ► Artikel lesen | |
| CERENO SCIENTIFIC Aktie jetzt für 0€ handeln | |||||
| 27.05. | Cereno Scientific - Firing on all cylinders | 382 | Edison Investment Research | In Q125, Cereno made tangible progress across both its clinical programmes. The period opened with new data for lead asset CS1 indicating disease-modifying signals, and was capped by FDA endorsement... ► Artikel lesen | |
| 27.05. | Cereno Scientific is nominated and shortlisted for 'Company of the Year' in the European Mediscience Awards 2025 | 1 | Cision News | ||
| 23.05. | Cereno Scientific AB: Cereno Scientific receives endorsement from FDA on plans for Phase IIb trial of CS1 in rare disease pulmonary arterial hypertension (PAH) | 149 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
| 22.05. | Cereno Scientific AB: Cereno Scientific publishes Interim Report for Q1 2025 (January 1 - March 31, 2025) | 233 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
| 15.05. | Cereno Scientific publishes Annual Report for 2024 | 1 | Cision News | ||
| 13.05. | Cereno Scientific presented CS1's Phase IIa trial results at the 5th Baltic Pulmonary Hypertension Conference 2025 | 2 | Cision News | ||
| 09.05. | Cereno Scientific give notice to attend the Annual General Meeting 2025 | 1 | Cision News | ||
| 07.05. | Correction: Cereno Scientific's Nomination Committee proposes new Board with M&A profile ahead of the Annual General Meeting on June 10, 2025 | 1 | Cision News | ||
| 07.05. | Cereno Scientific's Nomination Committee proposes new Board with M&A profile ahead of the Annual General Meeting on May 10, 2025 | 2 | Cision News | ||
| 07.05. | Cereno Scientific to present at ABGSC Investor Days on May 13-14, 2025, in Stockholm | 1 | Cision News | ||
| 23.04. | Cereno Scientific - CS1 takes another step towards Phase IIb | 327 | Edison Investment Research | Cereno Scientific has successfully completed its planned Type C meeting with the FDA for lead asset CS1. The minutes from the meeting will be available after 30 days, but Cereno has indicated that the... ► Artikel lesen | |
| 22.04. | Cereno Scientific aligns with FDA on CS1 development | 3 | Cision News |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 42,730 | +2,82 % | QIAGEN N.V.: QIAGEN Expands NGS Portfolio with Launch of QIAseq xHYB Long Read Panels | Expansion of QIAseq portfolio to Long Read Panels enables high-resolution analysis of complex genomic regions using long-read sequencing Supports NGS platforms such as PacBio for applications... ► Artikel lesen | |
| ABIVAX | 58,00 | +0,35 % | Abivax explodiert über 400%: Was bedeuten diese Daten? | Die französische Biotechfirma Abivax liefert starke Phase-3-Daten ihres Medikamentenkandidaten Obefazimod. Die Nasdaq-notierte Aktie schnellt über 400% durch die Decke. Was ist jetzt noch drin? Abivax... ► Artikel lesen | |
| EVOTEC | 6,358 | +2,05 % | Biotech-Hoffnung enttäuscht: Evotec kappt Umsatzprognose und die Aktie schmiert zweistellig ab | © Foto: Breuel-Bild/dpaEvotec hat die Umsatzprognose für das laufende Geschäftsjahr deutlich gesenkt. Das Hamburger Biotechunternehmen rechnet nun mit Konzernerlösen zwischen 760 und 800 Millionen Euro.... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 28,010 | 0,00 % | Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings | ||
| ARCELLX | 69,97 | +2,52 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 57,09 | +3,03 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies | The Breakthrough Therapy Designation (BTD) was granted based on the highly compelling results from the Phase 2 EMBOLD trial in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) The... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 55,74 | 0,00 % | ROUNDUP/Aktien New York Schluss: Gewinne - Arbeitsmarktdaten stützen | NEW YORK (dpa-AFX) - Die New Yorker Börsen haben am Dienstag nach einem verhaltenen Start ihre Kursgewinne ausgebaut. Marktbeobachter verwiesen darauf, dass die jüngsten Daten vom US-Arbeitsmarkt trotz... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,430 | 0,00 % | Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses? | ||
| BIONTECH | 96,90 | +3,36 % | BioNTech: Ryan Richardson verlässt Vorstand im Herbst | Bei BioNTech steht ein Wechsel im Vorstand bevor. Ryan Richardson wird seine Position als Chief Strategy Officer sowie seine Ämter in Tochtergesellschaften der BioNTech-Gruppe zum 30. September 2025... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 46,430 | 0,00 % | Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock? | ||
| ARCUTIS BIOTHERAPEUTICS | 14,910 | +2,47 % | Guggenheim maintains Buy rating on Arcutis Biotherapeutics stock amid prescription growth | ||
| DYNE THERAPEUTICS | 9,380 | +1,85 % | Dyne Therapeutics Prices Public Offering Of About 24.24 Mln Shares At $8.25/shr | WASHINGTON (dpa-AFX) - Dyne Therapeutics Inc. (DYN) announced the pricing of an underwritten public offering of about 24.24 million shares of its common stock at a public offering price of $8.25... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 18,000 | 0,00 % | ARS Pharmaceuticals, Inc.: EURneffy (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) | EURneffy (neffy® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children (>30 kg) living with severe allergic reactions ALK-Abelló A/S, which owns the rights to... ► Artikel lesen | |
| VERVE THERAPEUTICS | 11,110 | 0,00 % | Aktien New York Schluss: Verluste - Sorgen um Krieg in Nahost nehmen zu | NEW YORK (dpa-AFX) - Die sich zuspitzende Lage in Nahost und die Unsicherheit über das weitere Vorgehen der USA haben am Dienstag die US-Börsen belastet. Der New Yorker Leitindex Dow Jones Industrial... ► Artikel lesen | |
| NURIX THERAPEUTICS | 11,630 | 0,00 % | Nurix Therapeutics: Günstiger BTK-Player | In der Welt der Biotechnologie zählt die gezielte Zerstörung krankheitsverursachender Proteine zu den innovativsten Ansätzen der modernen Arzneimittelforschung. Nurix Therapeutics, ein Unternehmen mit... ► Artikel lesen |
CERENO SCIENTIFIC AB gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,018 (+2,25 %) liegt der Kurs bei 0,819 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CERENO SCIENTIFIC AB finden Sie auf Wallstreet Online.